Grant ID RP121048
Awarded On March 29, 2012
Title Development of therapeutic vaccines/drugs against prostate cancer by Blocking immune suppression
Program Academic Research
Award Mechanism Bridging the Gap: Early Translational Research Awards
Institution/Organization The Methodist Hospital Research Institute
Principal Investigator/Program Director Rongfu Wang
Cancer Sites Prostate
Contracted Amount $904,131
Lay Summary

Harnessing the immune system to eradicate malignant cells is a promising approach to cancer therapy. Recent FDA approval of sipuleucel-T (Provenge) for the treatment of metastatic prostate cancer and ipilimumab (Yervoy) for the treatment of melanoma represents milestones in the field of cancer immunotherapy. However, the clinical benefits reported for these agents have fallen far short of complete cures. Increasing evidence indicates that T cell-mediated immune suppression at tumor sites is a major obstacle to improving therapeutic efficacy of cancer vaccines and drugs. In efforts to overcome this barrier, we show that stimulation of human Toll-like receptor 8 with a Poly-Guanosine oligonucl...

Read More